34
Participants
Start Date
June 4, 2014
Primary Completion Date
December 16, 2019
Study Completion Date
June 15, 2020
Bendamustine
Days - 24 and Day - 23 followed by a short break of 10 - 14 days.
Carmustine
300 mg/m2 on Day -6
Etoposide
100 mg/m2 on days -5 to -2
Melphalan
140mg/m2 on Day -1
Cytarabine
200 mg/m2 on days -5 to -2
Alemtuzumab
20 mg/m2 days -6 to -2 for UNRELATED donors, and 20 mg/m2 days -4 to -2 for RELATED donors
Autologous Stem Cell Transplantation
Allogeneic Stem Cell Transplantation
Rituximab
Only to be administered in subjects with B-cell malignancies. Dose is 375 mg/m2 on Days 1 and 8 post-transplant
Weill Cornell Medical College, New York
Weill Medical College of Cornell University
OTHER